Gregory M. Lubiniecki
Merck & Co.
58 Papers
567 Citations
Gregory M. Lubiniecki is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pembrolizumab & Lung cancer. The author has an hindex of 28, co-authored 57 publications. Previous affiliations of Gregory M. Lubiniecki include University of California, Los Angeles.
Chat about Author
Papers
MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC
Balazs Halmos,Alexander Luft,Margarita Majem,Rina Hui,R. Corre,Mahmut Gumus,Konstantin Laktionov,Barbara Hermes,Irfan Cicin,Andrew G. Robinson,Terufumi Kato,Ying Cheng,Dariusz M. Kowalski,Xiaodong Li,Gregory M. Lubiniecki,Bilal Piperdi,Luis Paz-Ares +16 more
8
Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002.
Tara C. Gangadhar,Janice M. Mehnert,Amita Patnaik,Omid Hamid,Matteo S. Carlino,F. Stephen Hodi,Christian U. Blank,Antoni Ribas,Caroline Robert,Anna Georgieva Kondic,Malidi Ahamadi,Tomoko Freshwater,Rik de Greef,Marianne van Vugt,Gregory M. Lubiniecki,Scot Ebbinghaus,Soonmo Peter Kang,Adil Daud +17 more
TL;DR: The anti–PD-1 antibody pembro has efficacy in advanced cancer pts and the effect of clinical factors on exposure is quantified.
6
A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.
Roy S. Herbst,Alfonso Gurpide,Veerle Surmont,Dong Wan Kim,Saiama N. Waqar,Judith Herder,Dae Ho Lee,Enric Carcereny,Noemi Reguart,John M. Wallmark,Suresh S. Ramalingam,Corey J. Langer,Gregory M. Lubiniecki,James Knowles,Honghong Zhou,Mary E. Hanson,Paul Baas +16 more
TL;DR: This randomized phase II/III trial was designed to assess the clinical activity of MK-3475 monotherapy compared with standard docetaxel in patients with advanced NSCLC whose disease has progressed after platinum-containing therapy.
6
LBA3_PRKEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy
Roy S. Herbst,Dong Wook Kim,Enriqueta Felip,Jose Luis Perez-Gracia,Edward B. Garon,J-Y. Han,Julian R. Molina,Joo Hang Kim,Radj Gervais,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,G. De Castro,Marcelo Garrido,Gregory M. Lubiniecki,Yue Shentu,Ellie Im,Paul Baas +17 more
4
Abstract CT104: Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001)
Edward B. Garon,Naiyer A. Rizvi,Rina Hui,Natasha B. Leighl,Ani Sarkis Balmanoukian,Joseph Paul Eder,Amita Patnaik,Charu Aggarwal,Matthew A. Gubens,Leora Horn,Enric Carcereny,Myung-Ju Ahn,Enriqueta Felip,Jong Seok Lee,Jin Zhang,Reshma A. Rangwala,Gregory M. Lubiniecki,Charlotte Roach,Kenneth Emancipator,Leena Gandhi +19 more
TL;DR: These data validate that membranous PD-L1 expression in ≥50% of tumor cells identifies pts with advanced NSCLC who are particularly likely to obtain clinical benefit from pembro, and provide durable antitumor efficacy and safety in pts with treatment-naive and previously treated NSCLCs.
4